Salarius Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2016 - 2019
Net Income	-5.58	-12.54	-31.61	-12.77	-7.35	Upgrade
Depreciation & Amortization	0	0.01	0.01	0.02	0.02	Upgrade
Asset Writedown & Restructuring Costs	-	-	10.85	-	-	Upgrade
Stock-Based Compensation	0.27	0.52	0.8	0.56	0.32	Upgrade
Other Operating Activities	-	0.13	-0.01	-0.04	-0.26	Upgrade
Change in Accounts Receivable	-	1.48	-	2.25	-3.86	Upgrade
Change in Accounts Payable	0.33	-2.26	1.31	-0.31	-0	Upgrade
Change in Unearned Revenue	-	-	-	-	-0.54	Upgrade
Change in Other Net Operating Assets	0.44	-0.19	1.06	0.1	1.36	Upgrade
Operating Cash Flow	-4.53	-12.85	-17.6	-10.2	-10.31	Upgrade
Capital Expenditures	-	-	-	-	-0	Upgrade
Sale (Purchase) of Intangibles	-	-	-1.5	-	-	Upgrade
Investing Cash Flow	-	-	-1.5	-	-0	Upgrade
Short-Term Debt Repaid	-0.47	-0.28	-	-0.48	-0.97	Upgrade
Total Debt Repaid	-0.47	-0.28	-	-0.48	-0.97	Upgrade
Net Debt Issued (Repaid)	-0.47	-0.28	-	-0.48	-0.97	Upgrade
Issuance of Common Stock	1.53	6.92	1.99	28.77	18.67	Upgrade
Financing Cash Flow	1.06	6.64	1.99	28.3	17.69	Upgrade
Net Cash Flow	-3.47	-6.21	-17.11	18.1	7.38	Upgrade
Free Cash Flow	-4.53	-12.85	-17.6	-10.2	-10.31	Upgrade
Free Cash Flow Margin	-	-	-	-554.29%	-197.08%	Upgrade
Free Cash Flow Per Share	-4.70	-31.48	-66.26	-49.32	-132.41	Upgrade
Cash Interest Paid	0.01	0.01	-	0	0.01	Upgrade
Levered Free Cash Flow	-2.96	-8.99	-14.37	-3.89	-8.77	Upgrade
Unlevered Free Cash Flow	-2.96	-8.99	-14.37	-3.89	-8.77	Upgrade
Change in Net Working Capital	-0.35	1.46	-0.69	-3.54	4.24	Upgrade

Updated Mar 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q